8-K filing — MIRA PHARMACEUTICALS, INC. (MIRA)
Filed: 2026-08-06 AccNo: 0001493152-26-036262 Size: 234 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
MIRA Pharmaceuticals Says 7-Day Repeated-Dose Dog Study Of Obesity Candidate SKNY-1 Showed Dose-Dependent Exposure, Supporting Advancement Toward GLP Toxicology, IND-Enabling Work
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 12:15 PM
- Checked
- Aug 6, 2026, 12:15 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
MIRA Pharmaceuticals Says It Completed Dosing In Exploratory Non-GLP 7-Day Toxicology Studies Of MIRA-55 And SKNY-1, Advancing Both Toward IND-Enabling Development
Read original at benzingaMIRA Pharma Announces Results Preclinical Studies Evaluating Optimized Oral Formulations Of MIRA-55, Oral Drug Candidate Being Developed As Non-Opioid Therapy For Chronic Inflammatory Pain
Read original at benzinga